TOKYO -- After a year of record profits, Japan's Chugai Pharmaceutical is riding high in the stock market on hopes for an obesity drug under development, but its prospects could be dimmed if Robert F. Kennedy Jr. is confirmed as U.S. health secretary.
Pharmaceuticals
RFK Jr. could spell trouble for obesity drug from Japan's Chugai
U.S. health secretary nominee has criticized treatments buoying the company's shares
Hopes for orforglipron, an oral obesity drug licensed to Eli Lilly, have boosted Chugai Pharmaceutical's shares. (Chugai Pharmaceutical)
Read Next
Latest on Pharmaceuticals
